Author Contributions: Dr Suk Danik had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Suk Danik, Ridker.
Acquisition of data: Buring, Ridker.
Analysis and interpretation of data: Suk Danik, Rifai, Buring, Ridker.
Drafting of the manuscript: Suk Danik, Ridker.
Critical revision of the manuscript for important intellectual content: Suk Danik, Rifai, Buring, Ridker.
Statistical analysis: Suk Danik.
Obtained funding: Suk Danik, Buring, Ridker.
Administrative, technical, or material support: Ridker.
Study supervision: Ridker.
Financial Disclosures: Dr Suk Danik reported receiving grant support from the National Heart, Lung, and Blood Institute. Dr Rifai reported receiving grant support from Merck Research Laboratories, serving as a consultant to Sanofi-Aventis, and receiving honoraria from Ortho Diagnostics. Dr Buring reported receiving investigator-initiated research funding and support as a principal investigator from the National Institutes of Health (the National Heart, Lung, and Blood Institute, the National Cancer Institute, and the National Institute on Aging) and Dow Corning Corporation; receiving research support for pills and/or packaging from Bayer Heath Care and the Natural Source Vitamin E Association; receiving honoraria from Bayer for speaking engagements; and serving on an external scientific advisory committee for a study by Procter & Gamble. Dr Ridker reported receiving research grant support from the National Heart, Lung, and Blood Institute, the National Cancer Institute, the American Heart Association, the Doris Duke Charitable Foundation, the Leducq Foundation, the Donald W. Reynolds Foundation, and the James and Polly Annenberg La Vea Charitable Trusts; receiving investigator-initiated research support from Astra-Zeneca, Bayer, Bristol-Myers Squibb, Dade-Behring, Novartis, Pharmacia, Roche, Sanofi-Aventis, and Variagenics; being listed as a coinventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease; and serving as a consultant to Schering-Plough, Sanofi-Aventis, AstraZeneca, Isis Pharmaceutical, Dade-Behring, and Interleukin Genetics.
Funding/Support: This work was supported by grants from the Donald W. Reynolds Foundation (Las Vegas, Nev) and the Leducq Foundation (Paris, France). Dr Suk Danik was supported by grant HL-076443 from the National Heart, Lung, and Blood Institute. The Women's Health Study is supported by grant HL-43851 from the National Heart, Lung, and Blood Institute and grant CA-47988 from the National Cancer Institute.
Role of the Sponsor: The funding agencies played no role in the design, conduct, data management, analysis, or manuscript preparation.
Acknowledgment: We thank all the participants of the Women's Health Study. We also thank Nancy R. Cook, ScD, Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, for statistical expertise. Dr Cook received no compensation for her work.